Ani Pharmaceuticals(NASDAQ) ANIP

ANI Pharmaceuticals, Inc. makes medicines that treat rare diseases. The company helps patients manage several chronic health conditions. It also provides more affordable generic versions of common drugs.

From Rare Diseases to Generics

• Rare Disease Medicines: Targeted treatments for chronic autoimmune and eye conditions; net revenue reached $135.8 million for the three-month period ended June 30, 2026.
• Generic Pharmaceutical Products: Broad portfolio of non-branded medicines; net revenue was $99.1 million for the three-month period ended June 30, 2026.
• Branded Products: Established medicines like Atacand for blood pressure and Inderal LA for heart health; net revenue was $11.8 million for the three-month period ended June 30, 2026.

How Is ANI Expanding?

• Acquired Alimera Sciences on Sept. 16, 2024, to add eye treatments including ILUVIEN and YUTIQ to its portfolio.
• Secured FDA approval for a prefilled syringe version of Cortrophin Gel on Feb. 28, 2025.
• Expanded the use of ILUVIEN in March 2025 to treat chronic non-infectious uveitis affecting the posterior eye segment.
• Launched Cortrophin Gel in the U.S. market in Jan. 2022 for treating certain chronic autoimmune disorders.
• Purchased Novitium Pharma in 2021 to increase manufacturing and research capabilities for generic medicines.

Custom Facilities and Potent Medicines

ANI operates three specialized manufacturing facilities in Minnesota and New Jersey. These plants produce complex medicines including controlled substances and high-potency drugs that require fully-contained environments.

Growth by the Numbers

• Net revenues were $266.0 million for the three months ended June 30, 2026, up 25.9% year over year.
• Rare Disease and Brands revenue was $165.4 million for the three months ended June 30, 2026, up 41.2% year over year.
• Net income reached $24.7 million for the three-month period ended June 30, 2026.
• Total unrestricted cash and cash equivalents were $360.2 million as of June 30, 2026.
• Market capitalization was $1.9 billion as of the most recent reporting period.

Bottom Line

ANI has transformed into a diversified biopharmaceutical firm by focusing on rare disease therapies and specialty branded products. Its internal manufacturing capabilities and strategic acquisitions support a growing portfolio of complex and niche medicines.